Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Glaukos (GKOS)

Glaukos Preliminary 2023 Net Sales Exceed $313 Million; 2024 Guidance Reaffirmed

Positive Impact 3 of 5 earnings Written later

Glaukos said preliminary, unaudited net sales were expected to exceed $81 million for the fourth quarter and $313 million for fiscal 2023, compared with $283 million for 2022 as shown in its investor presentation. The company also reaffirmed its 2024 net sales guidance of $350 million to $360 million, so shareholders have a preliminary sales figure ahead of audited results and no change to the outlook.

Key points

  • Preliminary fourth-quarter 2023 net sales expected to be in excess of $81 million
  • Preliminary full-year 2023 net sales expected to be in excess of $313 million, versus $283 million in 2022 per the investor presentation
  • 2024 net sales guidance reaffirmed at $350 million to $360 million
  • Figures are preliminary and unaudited, per the press release dated January 9, 2024

The filing

CompanyGlaukos (GKOS)
Form8-K, current report
Filed with the SECJan 9, 2024, 7:00 AM ET
Accession number0001558370-24-000141

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 09, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.